The study discussed here was relatively small, involving only 17 patients, and more extensive clinical trials are needed to fully understand: Long-term safety profile Optimal dosing protocols Patient selection criteria Potential side effects Interactions with other treatments Additionally, patients should be aware that BPC-157 is not yet FDA-approved for human use, and treatment is typically offered on a research or compassionate use basis by qualified practitioners
Commonly reported side effects include mild pain, swelling, or itching at the injection site and sometimes nausea
Phentermine is a prescription medication that helps you lose weight by suppressing your appetite and prolonging the sensation of fullness in your stomach
This typically resolves within 24-48 hours and can be minimized by rotating injection sites
IGF-1 LR3 Reconstitution Reference (1 mg / 1,000 mcg vial) BAC water added 1 mL Concentration 1,000 mcg/mL 20 mcg dose 0.02 mL (2 units) 40 mcg dose 0.04 mL (4 units) 50 mcg dose 0.05 mL (5 units) 80 mcg dose 0.08 mL (8 units) 100 mcg dose 0.10 mL (10 units) BAC water added 2 mL Concentration 500 mcg/mL 20 mcg dose 0.04 mL (4 units) 40 mcg dose 0.08 mL (8 units) 50 mcg dose 0.10 mL (10 units) 80 mcg dose 0.16 mL (16 units) 100 mcg dose 0.20 mL (20 units) BAC water added 3 mL Concentration 333 mcg/mL 20 mcg dose 0.06 mL (6 units) 40 mcg dose 0.12 mL (12 units) 50 mcg dose 0.15 mL (15 units) 80 mcg dose 0.24 mL (24 units) 100 mcg dose 0.30 mL (30 units) Units refer to U-100 insulin syringe markings

Prescribers initiating BPC-157 in patients with Child-Pugh A or B hepatic impairment should document: (1) the clinical rationale for peptide therapy, (2) the absence of an FDA-approved alternative for the target condition, (3) baseline hepatic function with planned monitoring intervals, and (4) the patient's informed consent acknowledging the investigational nature of the therapy and the specific evidence limitations in their population